Rallybio Corporation reported earnings results for the full year ended December 31, 2023. For the full year, the company reported net loss was USD 74.56 million compared to USD 66.65 million a year ago. Basic loss per share from continuing operations was USD 1.84 compared to USD 2.09 a year ago.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.48 USD | -0.67% | -11.38% | -38.08% |
May. 15 | JPMorgan Downgrades Rallybio to Neutral From Overweight | MT |
May. 09 | Rallybio Corporation Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-38.08% | 61.34M | |
+51.85% | 57.87B | |
+41.25% | 40.25B | |
-5.25% | 39.94B | |
-5.16% | 28.54B | |
+12.79% | 26.4B | |
-20.18% | 19.33B | |
+30.88% | 12.4B | |
+0.61% | 12.23B | |
+25.06% | 12.2B |
- Stock Market
- Equities
- RLYB Stock
- News Rallybio Corporation
- Rallybio Corporation Reports Earnings Results for the Full Year Ended December 31, 2023